NTI Chart, page-217

Recently bought in. Thank you @Lefevre for highlighting this at TechKnow last year, I've been watching this.

Current capital structure is fantastic, but even more so the product and promising distribution deals.

First product already has FDA approval I believe the second version of the device will pass with flying colours if it's an updated iteration.

Let's not forget the global scientific team behind this company, I thought that was a great announcement. Plus one of the worlds top neuroscience universities backing this, and why wouldn't they the captured data is priceless.

If they are able to manage other diseases, that would be game changing - market cap $200M easily by years end imo.

Surprised this hasn't run, very early days in the company's history. Nice to see familiar investors on this. To me this is a safe investment with ongoing revenues. One of my top plays for 2017.